Desmopressin was first approved by the U.S. Food and Drug Administration (FDA) for medical use on November 1, 1978.

Desmopressin treats conditions such as diabetes insipidus, bedwetting (nocturnal enuresis), and von Willebrand disease.

Desmopressin can be administered orally in tablet form, as a nasal spray, or through injection. The specific usage instructions may vary depending on the condition being treated and the form of the medication. Oral tablets are typically taken with water, as directed by the healthcare provider. The nasal spray is administered by spraying into the nostrils, alternating nostrils with each dose. A healthcare professional usually gives injections under the skin or into a vein. 

One potential side effect of desmopressin is hyponatremia, characterized by low blood sodium levels. This medication can cause excessive water retention, leading to a dilution of sodium. Symptoms of hyponatremia may include headache, nausea, confusion, seizures, and in severe cases, coma.

Desmopressin carries important warnings. It can cause fluid retention, which may lead to water intoxication or hyponatremia (low sodium levels).

Precautions to consider when using desmopressin include closely monitoring fluid intake and output, as well as sodium levels, to prevent fluid imbalance. Patients should exercise caution in individuals with impaired kidney function or conditions associated with fluid overload. You need to be aware of potential interactions with other medications and inform healthcare providers of all medications being taken. Follow prescribed fluid restriction guidelines if applicable. Administer nasal spray properly and avoid tilting the head backward to prevent throat absorption after completion of treatment gradually tapering dosage under medical supervision to avoid a rebound effect.

Advice regarding Desmopressin is to always consult with a healthcare professional before starting or making any changes to your medication regimen. They can assess your medical history, evaluate potential risks and benefits, provide personalized guidance, and monitor your progress throughout treatment. Additionally, closely follow the instructions and recommendations your healthcare provider gives, promptly report any unusual or concerning symptoms, and communicate openly about any concerns or questions you may have. This medication can increase the risk of blood clotting. This is particularly relevant in individuals with a history of thromboembolic events or those who are at risk of developing blood clots. Close monitoring for signs of clotting disorders or complications is necessary during treatment. Precautions should be taken when using this medication in patients with liver or kidney impairment, as dosage adjustments or special monitoring may be required. Pregnant and breastfeeding individuals should consult with healthcare professionals before using this medication. Your healthcare professional is the best resource for ensuring safe and effective medication use.

1. Aspire Pharma; Electronic Medicines Compendium; [Revised: 2020] [Accesses: 17/July/2023]; https://www.medicines.org.uk/emc/files/pil.11939.pdf
2. Ferring Pharmaceuticals Ltd; Electronic Medicines Compendium; [Revised:2020] [Accessed: 17/July/2023]; https://www.medicines.org.uk/emc/product/3795/pil
3. TS McCarty, Shah AD; Desmopressin; NCBI Bookshelf; [Revised:2020] [Accessed:17/July/2023] ; https://www.ncbi.nlm.nih.gov/books/NBK554582/
4. Johan Vande Walle et al; Desmopressin 30 years in clinical use: A safety review; [Revised: 2007] [Accessed: 17/July/2023] ; https://pubmed.ncbi.nlm.nih.gov/18690973/

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.